It eradicates tumors and prevents their recurrence.
But now, researchers from Tufts School of Engineering have developed a new and potent vaccine for targeting cancer in mice,The vaccine works quite similarly to Pfizer and Moderna's COVID-19 vaccines, which deliver mRNA in tiny lipid bubbles that eventually fuse with body cells, enabling the cells to "read" the mRNA and produce viral antigens, which are tiny fragments of the virus that trigger the immune system.
“What we are doing now is developing the next generation of mRNA vaccines using lipid nanoparticle delivery technology, with the ability to target specific organs and tissues,” said Qiaobing Xu, one of the authors of the study and a professor of biomedical engineering. “Targeting the lymphatic system helped us to overcome many of the challenges that have faced others in developing a cancer vaccine.
After subcutaneously injecting them into mice, the researchers discovered an LNP that accumulated in the lymph nodes. They also suggest that LNPs gather blood-stream molecules on their surface, and those chosen molecules attach to certain receptors in the target organ.It was discovered that the present LNPs utilized in the Pfizer COVID-19 vaccine favored liver delivery over lymphatic system distribution by a four-to-one ratio.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Should parents delay kids’ second COVID vaccine? Here’s what the research saysIncreasing the interval between the first two mRNA-vaccine doses might boost children’s immunity, but it is a gamble as a new variant sweeps the globe.
Weiterlesen »
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results - Nature MedicineAn individualized, heterologous chimpanzee adenovirus (ChAd68) and self-amplifying mRNA-based neoantigen vaccine is safe and well tolerated in patients, warranting further studies to test its potential to rescue response to checkpoint blockade in tumors of low immune reactivity.
Weiterlesen »
CureVac sues BioNTech over mRNA technology - Nature BiotechnologyIn Brief: CureVacRNA files suit in Germany against BioNTech_Group, seeking compensation for infringement of four patents CureVac claims are used to make Comirnaty, the coronavirus vaccine developed by BioNTech and pfizer
Weiterlesen »
Monkeypox vaccine not 'a silver bullet', WHO says, as breakthrough cases emergeAs demand for monkeypox vaccines increases, the World Health Organization has begun to receive preliminary reports on the efficacy of the shots, which suggests there are breakthrough cases occurring, officials say.
Weiterlesen »